Salubris(SZ:002294) Western Securities·2026-03-31 08:37Investment Rating - The report gives an "Accumulate" rating for the company based on the continuous increase in innovative drug revenue and the acceleration of multiple key new drugs in clinical trials [2][5][17]. Core Insights - The company is a leading player in the domestic chronic disease management sector, focusing on comprehensive treatment solutions in the cardiovascular, renal, and metabolic fields. It has six approved innovative drugs, with over 50% of its revenue coming from innovative drugs, and 85 new drugs in the pipeline [1][5]. - The company is advancing its research on new targets and has a strong focus on managing the entire lifecycle of cardiovascular diseases, particularly hypertension and heart failure. The core commercial pipeline is expanding, with significant clinical trials underway [1][2][5]. - The company is also diversifying into metabolic and oncology fields, developing various drug types to address different clinical needs, including small molecules, monoclonal antibodies, and gene editing therapies [2][5]. Summary by Sections 1. Company Overview - The company has been deeply involved in chronic disease treatment for nearly 30 years, establishing itself as a leader in the field. It has a comprehensive product matrix that includes cardiovascular drugs, antibiotics, and orthopedic medications, with a focus on high-end interventional medical devices [24][25]. - The company has accelerated its innovation transformation since 2012, with a significant increase in its innovative drug pipeline, including the introduction of new drugs with global intellectual property rights [25][29]. 2. Focus on Cardiovascular Treatment - The company is addressing the high prevalence of cardiovascular and metabolic diseases, which often coexist, by developing a multi-target and multi-mechanism drug pipeline. This includes a range of drug types aimed at providing comprehensive management solutions for patients [51][56]. - The report highlights the need for new mechanisms and long-acting/oral formulations in the treatment of cardiovascular and metabolic diseases, given the current low treatment and control rates in China compared to developed countries [52][56]. 3. Financial Projections - The company is expected to achieve revenues of 44.29 billion, 53.58 billion, and 64.15 billion yuan from 2025 to 2027, with year-on-year growth rates of 10.4%, 21.0%, and 19.7% respectively. The net profit attributable to the parent company is projected to be 6.59 billion, 7.97 billion, and 9.49 billion yuan during the same period [2][17]. - The report indicates that the revenue structure is improving, with a significant increase in the proportion of innovative drug revenue, which is expected to enhance the company's profitability [35][38].